Trachoma, an infectious eye disease, is the world's leading cause of preventable blindness. WHO estimates that trachoma affects about 84 million people and about 8 million of them are visually impaired as a result of trachoma infection, with children and women disproportionately affected. The SAFE strategy, a comprehensive public health approach to trachoma control includes both treatment and prevention components. JSI provides support to The Task Force for Global Health's International Trachoma Initiative (ITI) for the "A" component of the SAFE strategy that focuses treating members of endemic communities through yearly mass drug administration (MDA) campaigns with the broad spectrum antibiotic azithromycin to interrupt the transmission of the infection. Pfizer donates Zithromax® (their branded product) in the fight against trachoma.
JSI public health logistics advisors and consultants have been providing technical services to the International Trachoma Initiative since 2003. Since the inception of our relationship with ITI, we've conducted 23 Zithromax® supply chain missions in nearly 20 countries, including Burundi, Cameroon, Ethiopia, Eritrea, Gambia, Ghana, Guinea Bissau, Malawi, Mali, Mauritania, Nepal, Niger, Nigeria, Southern Sudan, Tanzania, Uganda, United States, and Vietnam.